Physician profile
Robert K Pohl
NPI 1649333634
$1,144.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $602 · 2023: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $191.08 | 2022 | |
| Si-Bone, INC. | $183.63 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $132.39 | 2022 | |
| Alkermes, INC. | $100.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $99.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $95.50 | 2021 | |
| Abbott Laboratories | $95.09 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.77 | 2023 | |
| Novo Nordisk INC | $83.03 | 2022 | |
| Genentech USA, INC. | $72.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.